Study of Amaranth Medical's Drug-Eluting Bioresorbable Scaffold Supported by Boston Scientific

January 14, 2014—Amaranth Medical (Mountain View, CA) announced the closing of an equity investment by Boston Scientific Corporation (Natick, MA), which will be used to advance the clinical development of the Amaranth Fortitude drug-eluting bioresorbable scaffold in a planned international clinical study and subsequent application for CE Mark approval. In addition, the funding will support continued development of the next-generation Fortitude bioresorbable scaffold.

According to Amaranth Medical, the non–drug-eluting Fortitude scaffold was previously evaluated in a study of 13 patients with symptomatic coronary artery disease. The results of were presented at the TCT 2013: Transcatheter Cardiovascular Therapeutics meeting on October 27, 2013. The data suggested that the Fortitude scaffold maintained its mechanical integrity, with late lumen loss comparable to that observed with bare-metal stents. In 2014, Amaranth will begin enrolling a second cohort of patients to evaluate a drug-eluting Fortitude scaffold.